Reviews & Studies

Lexi-Comp is extremely proud of its products and services. Providing an industry-leading editorial model along with a sophisticated application interface has propelled our products to the highest levels. The links below provide many examples of studies validating Lexi-Comp's successes. These Peer Review Case Studies and Articles are unbiased accounts by your fellow peers and colleagues, rating Lexi-Comp's products and services against the competition.

Lexi-Comp's Peer Review and Studies:

"Online and PDA drug information databases assist practitioners in improving their clinical decision-making. Lexi-Drugs performed significantly better than all of the other PDA databases evaluated."

Clauson KA, Polen HH, Marsh WA. "Clinical Decision Support Tools:
Performance of Personal Digital Assistant versus Online Drug Information
Databases," Pharmacotherapy, 2007, 27(12): 1651-8.

Lexi-Drugs was found to be the most specific and complete resource available via PDA to optimize medication safety by reducing potential errors associated with drug information as a possible cause. Specific improvements and recommendations to maximize medication safety are discussed.

Number of episodes where sufficient information is available for each resource:
Lexi-Drugs®: 89% (42/47) mobile
MICROMEDEX®: 61% (29/47)
ePocrates®: 59% (28/47)

Journal of the Medical Library Association (JMLA) 93(2) April 2005

Personal digital assistant - based drug reference software as tools to improve rational prescribing: Benchmark criteria and performance

Lexi-Drugs achieved the #1 rating, a 73% (29 points) on a 0 to 40-point rating scale measuring the performance of 11 PDA-based drug reference software products. The drug references were assessed in six quality criteria areas: up-to-date information, evidence-based dosing information for labeled and unlabeled indications, side effects, drug interactions, herbals and nutritional supplements, and special features. In this same study, ePocrates was rated 4th at 55% (22 points), and mobileMDX was rated 9th at 45% (18 points).

Clinical Pharmacology & Therapeutics 2005, 78(1):7-18

"Lexi-Drugs, Rated #1."

Clauson KA, Seamon MJ, Clauson AS, and Van TB, - Evaluation of Drug Information Databases for Personal Digital Assistants.

Am J Health-Sys Pharm, 2004, 61:1015-24.

"Lexi-Interact excelled as a PDA pharmacopoeia for assessing drug interactions... thoughtfully designed to provide quickly accessible exceptionally reliable information... "

Barrons, R, - Evaluations of Personal Digital Assistant Software for Drug Interactions.
Am J Health-Sys Pharm, 2004, 61:380-5.

"Lexi-Drugs was the most accurate, specific and complete resource available via PDA to optimize medication safety by reducing potential errors associated with insufficient or incomplete drug information as a possible cause."

Galt, KA and Rule AM - PDA-Based Drug Information Sources: Potential to Assure Medication Safety.
Abstract: American College of Clinical Pharmacy 2003 Spring Practice and Research Forum.

"Lexi-Drugs offered the greatest breadth of information and the most clinically dependable content."

Enders SJ, Enders JM, and Holstad, SG, - Drug-Information Software for Palm Operating System Personal Digital Assistants:
Breadth, Clinical Dependability, and Ease of Use. Pharmacotherapy, 2002, 22(8):1036-40

"Lexi-Comp's Dentistry titles rated 100%"

Each year, Clinical Research Associates, Inc., tests in excess of 650 different product brands, performing about 20,000 field evaluations. These comprise of Clinical Field Trials, Controlled Clinical Tests, and Laboratory Tests. In 2004, all of the 15 CRA Evaluators stated that they would incorporate Lexi-Comp's Drug Information Handbook for Dentistry, Oral Hard Tissue Diseases, Oral Soft Tissue Diseases and Dental Office Medical Emergencies into their office, and 100% rated them excellent or good and worthy of trial by colleagues.